Back to Rankings

NRXP

NRXC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The primary-source picture improved modestly: Q1 revenue of about $1.1 million from Dura, net loss narrowed to about $1.4 million from $5.5 million a year earlier, and post-quarter ATM proceeds added roughly $7.0 million of cash support. If KETAFREE reaches a Summer 2026 approval path and NRX-100 is filed in Q2 2026, the stock could re-rate from a low base.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +6.3.
What can break
HOPE and Dura integration add execution risk because the current revenue base is still small and depends on successful clinic expansion and operational scaling. [#10-Q-2026-05-15]
Momentum
97
Value
41
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $6.00 · Bear $1.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $38.00
Why
Momentum97 · Δ7d +6.3
Value41 · Δ7d +0.1
Sentiment24 · Δ7d -30.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendImproving
Δ7d
+6.3
Δ21d
+4.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
24
33% active weight
Current posture
7d trendSoftening
Δ7d
-30.6
Δ21d
-20.8
Why this grade

Composite grade C. Momentum 97.4 / Value 41.1 / Sentiment 23.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$167.38M
Beta
1.92
Shares Out
28.1M
P/E (TTM) · Derived
-2.5
P/S (TTM)
279.82
P/FCF (TTM) · Derived
-8.20
Rev YoY
-
EPS YoY
-79.1%
Gross Margin
+59.9%
Op Margin
-8026.0%
Net Debt
$5.13M
Current Ratio
0.29
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology